Cardiovascular Medicine Book

http://www.fpnotebook.com/

Bretylium

Aka: Bretylium
  1. Indications
    1. Refractory Ventricular Fibrillation
    2. Refractory Ventricular Tachycardia
    3. Not a first line drug, use only after failed use of:
      1. Electrical cardioversion
      2. Epinephrine
      3. Lidocaine
    4. New ACLS Guidelines (2000) do not refer to Bretylium
      1. Natural Bretylium sources exhausted
      2. Severe adverse effects (Hypotension)
  2. Mechanism
    1. Background
      1. Adrenergic Neuronal blocking drug
      2. Originally used as an antihypertensive in 1950s
    2. Adrenergic Effects (Biphasic) in non-Cardiac Arrest
      1. Initial (Lasts first 20 minutes after dose)
        1. Stimulates Norepinephrine release
        2. Results in Hypertension and Tachycardia
      2. Subsequent (begins at 20 min and peaks at 60 min)
        1. Inhibits Norepinephrine release
        2. Results in Hypotension
    3. Effects on Fibrillation and Defibrillation
      1. Increases Ventricular Fibrillation threshold
        1. Lidocaine also increases fibrillation threshold
      2. Does not increase Defibrillation threshold
        1. Lidocaine does increase Defibrillation threshold
      3. Synergistic response when used with Lidocaine
  3. Dose
    1. General
      1. Administer as rapid IV push
      2. Flush the IV line with saline immediately after bolus
    2. Pediatrics and Adult
      1. Initial: 5 mg/kg rapid IV push
      2. Subsequent: 10 mg/kg rapid IV push
        1. May be repeated every 5-20 min up to twice
        2. Max total dose of 35 mg/kg
  4. Adverse Effects
    1. Postural Hypotension (non-Cardiac Arrest patient)
      1. Seen in 60% of patients
      2. Arterial Pressure usually falls less than 20 mmHg
      3. Treatment of symptomatic Hypotension
        1. Trendelenburg's position
        2. Vasopressors (e.g. Norepinephrine) rarely needed
    2. Initial transient effects
      1. Nausea or Vomiting
      2. Hypertension
      3. Tachycardia
  5. Precautions
    1. May exacerbate Digitalis Toxicity!
      1. Occurs with Bretylium mediated Catecholamine release
  6. References
    1. (2000) Circulation 102(suppl I): 86-89
    2. Katzung (1989) Pharmacology, Lange, p. 179

bretylium (C0054040)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C045166
SnomedCT 372774002, 56230001
LNC LP14708-9, MTHU001804
English bretylium, bretylium [Chemical/Ingredient], Bretylium, Bretylium (product), Bretylium (substance), BRETYLIUM
Spanish bretilio (producto), bretilio (sustancia), bretilio
Sources
Derived from the NIH UMLS (Unified Medical Language System)


You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree